Immunocore Holdings plc
NASDAQ:IMCRBiotechnology
+$0.18 today
- Market cap
- $1.42B
- Beta
- 0.75
- P/E (TTM)
- -77.5
- EPS (TTM)
- -$0.37
Volume 0.30M
Average 0.40M
IMCR Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Immunocore Holdings plcNASDAQ: IMCR
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $946.41K rose 10.8% year over year, ahead of the -17.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 13.5% from the prior quarter. Over 3 fiscal years it compounded at -23.1% a year.
Context
- Depreciation & amortization amounted to 0.8% of revenue in FY2025, down 0.9 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +10.8% holds above the trailing-twelve-month pace of -17.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
Mixed currencies · from the cash flow
- Latest · FY2025
- 2.43M USD
- Year-over-year change
- -42.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.43M | -42.2% |
| FY2024 | 2024-12-31 | 4.2M | — |
| FY2023 | 2023-12-31 | 3.24M | -39.3% |
| FY2022 | 2022-12-31 | 5.34M | -29.7% |
| FY2021 | 2021-12-31 | 7.59M | — |
Depreciation & Amortization vs competitors
How IMCR compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -17.0% is the lowest of 10, against a peer median of +0.0%.
- Depreciation & amortization amounts to 0.9% of revenue for IMCR, versus a peer median of 9.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €676.85M EUR | +122.9% | +43.9% | 25.6% | |
| LTM Sep 2026 | $16.54M USD | +4.6% | -5.3% | 9.1% | |
| LTM Mar 2026 | €12.05M EUR | -2.4% | +19.6% | 32.3% | |
| LTM Jun 2026 | $10.17M USD | -10.7% | +6.1% | 9.7% | |
| LTM Jun 2026 | $10M USD | +0.0% | +18.6% | 8.5% | |
| LTM Mar 2026 | $6.94M USD | -7.1% | -22.5% | 4.4% | |
| FY2025 | €5.09M EUR | +155.3% | -51.8% | 182.7% | |
| LTM Mar 2026 | $3.36M USD | -17.0% | -23.1% | 0.9% | |
| FY2025 | A$2.39M AUD | +5.6% | +5.0% | 47.4% | |
| LTM Mar 2026 | $1.98M USD | -3.3% | +34.1% | 9.2% | |
| LTM Dec 2025 | $0 USD | — | -0.5% | 0.0% | |
| Peer median (excluding IMCR) | — | +0.0% | +5.6% | 9.4% | |
Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 · GBP | FY2022 Dec 2022 · GBP | FY2023 Dec 2023 · GBP | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | (180.03M) | (52.54M) | (34.32M) | (51.09M) | (26.42M) |
| Depreciation & Amortization | 7.59M | 5.34M | 3.24M | 4.2M | 2.43M |
| Deferred Income Tax | (12.69M) | (3.53M) | 0 | 0 | 11M |
| Stock-Based Compensation | 48.89M | 32.89M | 25.69M | 34.19M | 0 |
| Change in Working Capital | (21.96M) | (24.17M) | 4.58M | 45.13M | (6.92M) |
| Accounts Receivables | (4.86M) | (26.26M) | (14.14M) | (12.35M) | (5.46M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.47M | 4.91M | 2.08M | 7.27M | (1.83M) |
| Other Working Capital | (18.57M) | (2.81M) | 16.64M | 50.21M | 366K |
| Other Non-Cash Items | 15.09M | (7.19M) | 3.14M | (6.38M) | 11.94M |
| Operating Cash Flow | (143.11M) | (49.21M) | 2.33M | 26.06M | (7.97M) |
| Capital Expenditures | (1.39M) | (2.2M) | (4.29M) | (5.17M) | (3.23M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (350M) | (22.32M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 13.39M |
| Other Investing Activities | 106K | 6K | (925.46K) | 44K | 0 |
| Investing Cash Flow | (1.28M) | (2.2M) | (4.29M) | (355.13M) | (12.16M) |
| Debt Repayment | 0 | 0 | 0 | 352.5M | 0 |
| Common Stock Issued | 286.89M | 139.52M | 0 | 6.8M | 9.2M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.3M | 5.93M | 27.18M | (15.42M) | 0 |
| Financing Cash Flow | 288.19M | 145.44M | 27.18M | 343.88M | 9.2M |
| Effect of Forex Changes | 625K | (12.65M) | 6.56M | (1.71M) | 19.81M |
| Net Change in Cash | 144.42M | 81.39M | 31.78M | 13.11M | 8.89M |
| Free Cash Flow | (144.49M) | (51.41M) | (1.97M) | 20.89M | (11.2M) |
Immunocore Holdings plc
NASDAQ:IMCR
Intrinsic Alpha fair value
Locked
Current Price
$27.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.